H.B. Fuller Company, together with its subsidiaries, formulates, manufactures, and markets adhesives, sealants, coatings, polymers, tapes, encapsulants, additives, and other specialty chemical products. It operates through three segments: Hygiene, Health and Consumable Adhesives; Engineering Adhesives; and Construction Adhesives. The Hygiene, Health and Consumable Adhesives segment produces and supplies specialty industrial adhesives, such as thermoplastic, thermoset, reactive, water-based, and solvent-based products for applications in various markets, including packaging, converting, nonwoven and hygiene, and health and beauty. The Engineering Adhesives segment produces and supplies high performance industrial adhesives comprising reactive, light cure, two-part liquids, polyurethane, silicone, film, and fast cure products to the durable assembly, performance wood and textile, transportation, electronics, clean energy, aerospace and defense, appliance, heavy machinery, and insulating glass markets. The Construction Adhesives segment provides products used for tile setting, commercial roofing, heating, ventilation, and air conditioning and insulation applications, as well as caulks and sealants for the consumer market and professional trade. The company sells its products directly to customers, as well as through distributors and retailers in North America, Latin America, Europe, India, the Middle East, Africa, and the Asia Pacific. H.B. Fuller Company was founded in 1887 and is headquartered in Saint Paul, Minnesota.

H. B. Fuller Company

The latest update is out from Fulcrum Lithium Ltd. ( ($AU:FUL) ). Fulcrum Lithium Ltd. has announced the results of a geophysical survey at its Alk...

Fulcrum Lithium Expands Alkali Flats Targets with New Survey

Fulcrum Therapeutics (($FULC)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Fulcrum The...

Fulcrum Therapeutics’ Earnings Call Highlights Progress and Potential

Fulcrum Therapeutics ( ($FULC) ) has released its Q3 earnings. Here is a breakdown of the information Fulcrum Therapeutics presented to its investo...

Fulcrum Therapeutics Reports Q3 2025 Progress and Financials

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Quoin Pharmaceuticals (QNRX – Research Report) and F...

Analysts Are Bullish on Top Healthcare Stocks: Quoin Pharmaceuticals (QNRX), Fulcrum Therapeutics (FULC)

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Fulcrum Therapeutics today and set a price target of $15.00. The company’s shares op...

Oppenheimer Reaffirms Their Buy Rating on Fulcrum Therapeutics (FULC)

In a report released today, Michael Harrison CFA from Seaport Global reiterated a Buy rating on H.B. Fuller Company, with a price target of $80.00....

Market Cap	$3.14B	P/E Ratio	13.62
52W High	$78.68	52W Low	$47.56
Div Yield	94.0%	Payout Ratio	-83.6%
EPS Growth 3Y	-8.1%	52W Position	31.4%
Overall Score	65	Value Score	85
Quality Score	--	Technical Score	45

EPS Current Est	$4.21	EPS Next Est	$4.69
EPS Growth Est	+11.4%	DPS Growth 3Y	8.7%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FUL	$57.34	+3.48%	424.27K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FUL	$57.34	+3.5%	424.27K
3
4
5
6

FUL

FUL

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get H. B. Fuller Company Data in Excel

Get H. B. Fuller Company Data in Excel